Stem definition | Drug id | CAS RN |
---|---|---|
sodium glucose co-transporter inhibitors, phlorizin derivatives | 4304 | 461432-26-8 |
Dose | Unit | Route |
---|---|---|
10 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Hosey CM, Chan R, Benet LZ |
Vd (Volume of distribution) | 1.70 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 3 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.09 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 12.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
March 24, 2014 | PMDA | BRISTOL-MYERS | |
Jan. 8, 2014 | FDA | ASTRAZENECA AB | |
Nov. 12, 2012 | EMA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Diabetic ketoacidosis | 3100.88 | 18.82 | 719 | 9724 | 17153 | 50577528 |
Ketoacidosis | 1369.35 | 18.82 | 281 | 10162 | 3614 | 50591067 |
Euglycaemic diabetic ketoacidosis | 935.45 | 18.82 | 194 | 10249 | 2625 | 50592056 |
Fungal infection | 354.82 | 18.82 | 156 | 10287 | 29809 | 50564872 |
Ketosis | 179.15 | 18.82 | 37 | 10406 | 486 | 50594195 |
Diabetes mellitus inadequate control | 147.56 | 18.82 | 66 | 10377 | 13079 | 50581602 |
Glycosylated haemoglobin increased | 137.70 | 18.82 | 59 | 10384 | 10547 | 50584134 |
Ketonuria | 130.65 | 18.82 | 28 | 10415 | 444 | 50594237 |
Urinary tract infection | 127.21 | 18.82 | 191 | 10252 | 223829 | 50370852 |
Blood glucose increased | 102.85 | 18.82 | 98 | 10345 | 71226 | 50523455 |
Hypoglycaemia | 91.59 | 18.82 | 81 | 10362 | 53500 | 50541181 |
Lactic acidosis | 90.25 | 18.82 | 66 | 10377 | 33289 | 50561392 |
Blood ketone body increased | 86.07 | 18.82 | 18 | 10425 | 252 | 50594429 |
Diabetic metabolic decompensation | 81.07 | 18.82 | 24 | 10419 | 1456 | 50593225 |
Acute kidney injury | 76.18 | 18.82 | 154 | 10289 | 227904 | 50366777 |
Glomerular filtration rate decreased | 74.93 | 18.82 | 40 | 10403 | 11612 | 50583069 |
Urine ketone body present | 74.26 | 18.82 | 25 | 10418 | 2308 | 50592373 |
Weight decreased | 71.04 | 18.82 | 147 | 10296 | 221098 | 50373583 |
Dehydration | 69.81 | 18.82 | 118 | 10325 | 152331 | 50442350 |
Metabolic acidosis | 68.95 | 18.82 | 60 | 10383 | 38765 | 50555916 |
Diabetic ketosis | 68.12 | 18.82 | 14 | 10429 | 179 | 50594502 |
Hyperglycaemia | 58.16 | 18.82 | 53 | 10390 | 36352 | 50558329 |
Vulvovaginal pruritus | 53.72 | 18.82 | 20 | 10423 | 2476 | 50592205 |
Pyelonephritis | 53.06 | 18.82 | 35 | 10408 | 14954 | 50579727 |
Necrotising fasciitis | 52.89 | 18.82 | 20 | 10423 | 2584 | 50592097 |
Genital infection female | 51.76 | 18.82 | 10 | 10433 | 91 | 50594590 |
Pruritus genital | 51.74 | 18.82 | 14 | 10429 | 612 | 50594069 |
Temperature perception test abnormal | 50.78 | 18.82 | 8 | 10435 | 17 | 50594664 |
Glucose urine present | 45.83 | 18.82 | 13 | 10430 | 677 | 50594004 |
Left ventricular dysfunction | 43.29 | 18.82 | 27 | 10416 | 10479 | 50584202 |
Candida infection | 43.05 | 18.82 | 37 | 10406 | 23486 | 50571195 |
Pollakiuria | 40.60 | 18.82 | 36 | 10407 | 23815 | 50570866 |
Urosepsis | 40.45 | 18.82 | 30 | 10413 | 15435 | 50579246 |
Cerebral infarction | 39.58 | 18.82 | 34 | 10409 | 21570 | 50573111 |
Polyuria | 39.02 | 18.82 | 22 | 10421 | 7099 | 50587582 |
Genital infection | 37.61 | 18.82 | 7 | 10436 | 51 | 50594630 |
Genital infection fungal | 34.98 | 18.82 | 8 | 10435 | 173 | 50594508 |
Decreased vibratory sense | 32.60 | 18.82 | 8 | 10435 | 236 | 50594445 |
Drug ineffective | 31.93 | 18.82 | 77 | 10366 | 819256 | 49775425 |
Acidosis | 31.70 | 18.82 | 22 | 10421 | 10205 | 50584476 |
Bladder trabeculation | 31.11 | 18.82 | 6 | 10437 | 54 | 50594627 |
Haematuria | 30.94 | 18.82 | 32 | 10411 | 25581 | 50569100 |
Pancreatitis | 29.43 | 18.82 | 40 | 10403 | 42574 | 50552107 |
Cardiac failure | 28.50 | 18.82 | 54 | 10389 | 75986 | 50518695 |
Vulvovaginal mycotic infection | 27.58 | 18.82 | 15 | 10428 | 4514 | 50590167 |
Blood glucose abnormal | 27.12 | 18.82 | 17 | 10426 | 6655 | 50588026 |
Dysuria | 26.44 | 18.82 | 31 | 10412 | 28473 | 50566208 |
Peripartum cardiomyopathy | 26.22 | 18.82 | 6 | 10437 | 130 | 50594551 |
Toe amputation | 26.20 | 18.82 | 11 | 10432 | 1866 | 50592815 |
Urinary tract infection fungal | 25.69 | 18.82 | 8 | 10435 | 576 | 50594105 |
Compartment syndrome | 25.63 | 18.82 | 11 | 10432 | 1971 | 50592710 |
Blood ketone body | 25.54 | 18.82 | 5 | 10438 | 49 | 50594632 |
Suspected COVID-19 | 25.32 | 18.82 | 10 | 10433 | 1451 | 50593230 |
Pain | 25.28 | 18.82 | 51 | 10392 | 578852 | 50015829 |
Hyperglycaemic hyperosmolar nonketotic syndrome | 25.22 | 18.82 | 8 | 10435 | 612 | 50594069 |
Vomiting | 24.72 | 18.82 | 171 | 10272 | 460587 | 50134094 |
Arteriosclerosis | 24.62 | 18.82 | 18 | 10425 | 9059 | 50585622 |
Capillary leak syndrome | 22.84 | 18.82 | 10 | 10433 | 1880 | 50592801 |
Dizziness | 22.52 | 18.82 | 135 | 10308 | 346234 | 50248447 |
Perineal pain | 22.43 | 18.82 | 6 | 10437 | 251 | 50594430 |
Latent autoimmune diabetes in adults | 22.31 | 18.82 | 4 | 10439 | 23 | 50594658 |
Portal fibrosis | 22.13 | 18.82 | 6 | 10437 | 264 | 50594417 |
Thirst | 22.06 | 18.82 | 18 | 10425 | 10632 | 50584049 |
Upper airway obstruction | 21.69 | 18.82 | 7 | 10436 | 566 | 50594115 |
Food refusal | 21.09 | 18.82 | 6 | 10437 | 316 | 50594365 |
Atrioventricular block complete | 21.07 | 18.82 | 15 | 10428 | 7240 | 50587441 |
Contraindicated product administered | 20.80 | 18.82 | 3 | 10440 | 148955 | 50445726 |
Glycosuria | 20.77 | 18.82 | 8 | 10435 | 1086 | 50593595 |
Pyelonephritis acute | 20.72 | 18.82 | 12 | 10431 | 4071 | 50590610 |
Toxicity to various agents | 20.66 | 18.82 | 9 | 10434 | 212490 | 50382191 |
Rheumatoid arthritis | 20.63 | 18.82 | 8 | 10435 | 202542 | 50392139 |
Aortic valve calcification | 19.70 | 18.82 | 6 | 10437 | 401 | 50594280 |
Vulvovaginal candidiasis | 19.46 | 18.82 | 10 | 10433 | 2682 | 50591999 |
Orthopnoea | 19.44 | 18.82 | 13 | 10430 | 5676 | 50589005 |
Diabetic ketoacidotic hyperglycaemic coma | 19.33 | 18.82 | 4 | 10439 | 53 | 50594628 |
Metabolic alkalosis | 19.33 | 18.82 | 10 | 10433 | 2721 | 50591960 |
Hyperkalaemia | 19.07 | 18.82 | 35 | 10408 | 48054 | 50546627 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Diabetic ketoacidosis | 2177.06 | 17.82 | 601 | 10676 | 15472 | 29547778 |
Ketoacidosis | 782.36 | 17.82 | 197 | 11080 | 3442 | 29559808 |
Euglycaemic diabetic ketoacidosis | 618.26 | 17.82 | 153 | 11124 | 2477 | 29560773 |
Glycosylated haemoglobin increased | 207.00 | 17.82 | 91 | 11186 | 9335 | 29553915 |
Ketosis | 175.26 | 17.82 | 39 | 11238 | 384 | 29562866 |
Ketonuria | 147.60 | 17.82 | 36 | 11241 | 544 | 29562706 |
Phimosis | 136.64 | 17.82 | 35 | 11242 | 652 | 29562598 |
Balanoposthitis | 128.08 | 17.82 | 36 | 11241 | 966 | 29562284 |
Blood glucose increased | 107.22 | 17.82 | 122 | 11155 | 58862 | 29504388 |
Fungal infection | 104.32 | 17.82 | 65 | 11212 | 13620 | 29549630 |
Diabetic ketosis | 99.26 | 17.82 | 19 | 11258 | 80 | 29563170 |
Glomerular filtration rate abnormal | 91.78 | 17.82 | 26 | 11251 | 718 | 29562532 |
Metabolic acidosis | 89.79 | 17.82 | 90 | 11187 | 37572 | 29525678 |
Glomerular filtration rate decreased | 89.64 | 17.82 | 55 | 11222 | 11211 | 29552039 |
Lactic acidosis | 88.63 | 17.82 | 81 | 11196 | 30166 | 29533084 |
Diabetes mellitus inadequate control | 88.38 | 17.82 | 56 | 11221 | 12078 | 29551172 |
Polyuria | 82.74 | 17.82 | 45 | 11232 | 7317 | 29555933 |
N-terminal prohormone brain natriuretic peptide increased | 81.98 | 17.82 | 30 | 11247 | 1902 | 29561348 |
Toe amputation | 78.79 | 17.82 | 30 | 11247 | 2125 | 29561125 |
Hypoglycaemia | 74.57 | 17.82 | 92 | 11185 | 48254 | 29514996 |
Bladder cancer | 74.40 | 17.82 | 47 | 11230 | 10080 | 29553170 |
Weight decreased | 73.36 | 17.82 | 171 | 11106 | 150734 | 29412516 |
Blood ketone body increased | 68.86 | 17.82 | 18 | 11259 | 364 | 29562886 |
Urinary tract infection | 67.27 | 17.82 | 108 | 11169 | 72246 | 29491004 |
Type V hyperlipidaemia | 66.70 | 17.82 | 20 | 11257 | 677 | 29562573 |
Necrotising fasciitis | 65.88 | 17.82 | 30 | 11247 | 3335 | 29559915 |
Pollakiuria | 65.17 | 17.82 | 53 | 11224 | 16863 | 29546387 |
Dehydration | 61.23 | 17.82 | 135 | 11142 | 114613 | 29448637 |
Epididymitis | 60.57 | 17.82 | 25 | 11252 | 2190 | 29561060 |
Acquired phimosis | 60.19 | 17.82 | 12 | 11265 | 65 | 29563185 |
Urine ketone body present | 54.79 | 17.82 | 19 | 11258 | 1029 | 29562221 |
Blood pressure decreased | 52.32 | 17.82 | 75 | 11202 | 45402 | 29517848 |
Cerebral infarction | 49.85 | 17.82 | 54 | 11223 | 24621 | 29538629 |
Hyperglycaemia | 47.68 | 17.82 | 62 | 11215 | 34225 | 29529025 |
Glucose urine present | 44.61 | 17.82 | 16 | 11261 | 957 | 29562293 |
Urosepsis | 44.21 | 17.82 | 35 | 11242 | 10711 | 29552539 |
Hyperglycaemic hyperosmolar nonketotic syndrome | 43.12 | 17.82 | 16 | 11261 | 1054 | 29562196 |
Cardiac failure | 43.05 | 17.82 | 94 | 11183 | 79193 | 29484057 |
Acute kidney injury | 42.17 | 17.82 | 206 | 11071 | 265061 | 29298189 |
Thirst | 40.02 | 17.82 | 27 | 11250 | 6464 | 29556786 |
Mitral valve thickening | 36.98 | 17.82 | 11 | 11266 | 362 | 29562888 |
Toxicity to various agents | 35.61 | 17.82 | 11 | 11266 | 173650 | 29389600 |
Glycosuria | 34.79 | 17.82 | 14 | 11263 | 1148 | 29562102 |
Thrombotic cerebral infarction | 34.07 | 17.82 | 10 | 11267 | 314 | 29562936 |
Mitral valve calcification | 33.05 | 17.82 | 11 | 11266 | 525 | 29562725 |
Ejection fraction decreased | 32.32 | 17.82 | 35 | 11242 | 15943 | 29547307 |
Neutropenia | 31.56 | 17.82 | 6 | 11271 | 131705 | 29431545 |
Blood glucose abnormal | 30.99 | 17.82 | 21 | 11256 | 5062 | 29558188 |
Thrombocytopenia | 30.54 | 17.82 | 7 | 11270 | 134816 | 29428434 |
Genital rash | 30.34 | 17.82 | 10 | 11267 | 463 | 29562787 |
N-terminal prohormone brain natriuretic peptide abnormal | 29.34 | 17.82 | 8 | 11269 | 191 | 29563059 |
Foot amputation | 29.33 | 17.82 | 10 | 11267 | 514 | 29562736 |
Acute myocardial infarction | 29.24 | 17.82 | 60 | 11217 | 48378 | 29514872 |
Perineal abscess | 28.55 | 17.82 | 8 | 11269 | 212 | 29563038 |
Body mass index increased | 28.33 | 17.82 | 11 | 11266 | 821 | 29562429 |
Gangrene | 27.09 | 17.82 | 18 | 11259 | 4200 | 29559050 |
Microalbuminuria | 26.96 | 17.82 | 10 | 11267 | 658 | 29562592 |
Obesity | 26.14 | 17.82 | 25 | 11252 | 9838 | 29553412 |
Total cholesterol/HDL ratio increased | 25.80 | 17.82 | 7 | 11270 | 164 | 29563086 |
Genital infection fungal | 25.60 | 17.82 | 7 | 11270 | 169 | 29563081 |
Febrile neutropenia | 25.07 | 17.82 | 6 | 11271 | 112234 | 29451016 |
Mitral valve incompetence | 24.95 | 17.82 | 28 | 11249 | 13265 | 29549985 |
Pancreatitis | 24.77 | 17.82 | 46 | 11231 | 34468 | 29528782 |
Cardiac failure chronic | 24.34 | 17.82 | 20 | 11257 | 6447 | 29556803 |
Pancreatitis acute | 23.43 | 17.82 | 37 | 11240 | 24348 | 29538902 |
Hyperuricaemia | 23.24 | 17.82 | 20 | 11257 | 6869 | 29556381 |
Hypertrophy | 22.89 | 17.82 | 8 | 11269 | 443 | 29562807 |
Genital infection male | 22.78 | 17.82 | 4 | 11273 | 9 | 29563241 |
Peripheral circulatory failure | 22.47 | 17.82 | 6 | 11271 | 132 | 29563118 |
Urine output increased | 22.44 | 17.82 | 10 | 11267 | 1056 | 29562194 |
Renal atrophy | 22.25 | 17.82 | 10 | 11267 | 1077 | 29562173 |
Acetonaemia | 22.10 | 17.82 | 6 | 11271 | 141 | 29563109 |
Immune-mediated hepatitis | 21.91 | 17.82 | 11 | 11266 | 1516 | 29561734 |
Brain stem infarction | 21.88 | 17.82 | 10 | 11267 | 1120 | 29562130 |
Vaccination failure | 21.69 | 17.82 | 8 | 11269 | 518 | 29562732 |
Bladder cancer recurrent | 21.43 | 17.82 | 7 | 11270 | 315 | 29562935 |
Diabetes mellitus | 21.33 | 17.82 | 47 | 11230 | 39784 | 29523466 |
Haematuria | 21.32 | 17.82 | 50 | 11227 | 44089 | 29519161 |
Disease progression | 21.24 | 17.82 | 3 | 11274 | 81913 | 29481337 |
Hypoglycaemic coma | 20.96 | 17.82 | 12 | 11265 | 2151 | 29561099 |
Polycythaemia | 20.53 | 17.82 | 11 | 11266 | 1733 | 29561517 |
Drug ineffective | 20.25 | 17.82 | 71 | 11206 | 363099 | 29200151 |
Type 2 diabetes mellitus | 19.56 | 17.82 | 25 | 11252 | 13556 | 29549694 |
Pancytopenia | 19.47 | 17.82 | 4 | 11273 | 83164 | 29480086 |
Pyrexia | 19.02 | 17.82 | 52 | 11225 | 287570 | 29275680 |
Pyelonephritis | 18.89 | 17.82 | 16 | 11261 | 5377 | 29557873 |
Dysuria | 18.79 | 17.82 | 32 | 11245 | 22408 | 29540842 |
Anaemia | 18.59 | 17.82 | 30 | 11247 | 200921 | 29362329 |
Malignant neoplasm progression | 18.47 | 17.82 | 3 | 11274 | 73856 | 29489394 |
Concomitant disease aggravated | 17.91 | 17.82 | 15 | 11262 | 4963 | 29558287 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Diabetic ketoacidosis | 4112.57 | 16.15 | 1065 | 17416 | 28780 | 64451471 |
Ketoacidosis | 1605.04 | 16.15 | 376 | 18105 | 6487 | 64473764 |
Euglycaemic diabetic ketoacidosis | 1352.55 | 16.15 | 313 | 18168 | 5097 | 64475154 |
Ketosis | 291.10 | 16.15 | 65 | 18416 | 888 | 64479363 |
Glycosylated haemoglobin increased | 253.91 | 16.15 | 113 | 18368 | 15906 | 64464345 |
Ketonuria | 223.32 | 16.15 | 54 | 18427 | 1063 | 64479188 |
Diabetes mellitus inadequate control | 205.73 | 16.15 | 107 | 18374 | 21214 | 64459037 |
Lactic acidosis | 166.28 | 16.15 | 139 | 18342 | 61271 | 64418980 |
Metabolic acidosis | 160.61 | 16.15 | 145 | 18336 | 70813 | 64409438 |
Hypoglycaemia | 151.20 | 16.15 | 156 | 18325 | 89736 | 64390515 |
Diabetic ketosis | 145.74 | 16.15 | 31 | 18450 | 332 | 64479919 |
Fungal infection | 142.17 | 16.15 | 100 | 18381 | 34151 | 64446100 |
Blood glucose increased | 138.22 | 16.15 | 155 | 18326 | 97918 | 64382333 |
Dehydration | 119.76 | 16.15 | 219 | 18262 | 216544 | 64263707 |
Acute kidney injury | 115.31 | 16.15 | 335 | 18146 | 448905 | 64031346 |
Glomerular filtration rate decreased | 112.42 | 16.15 | 70 | 18411 | 19502 | 64460749 |
Cerebral infarction | 105.08 | 16.15 | 90 | 18391 | 40954 | 64439297 |
Polyuria | 103.78 | 16.15 | 57 | 18424 | 12586 | 64467665 |
Hyperglycaemia | 102.80 | 16.15 | 106 | 18375 | 60862 | 64419389 |
Weight decreased | 99.58 | 16.15 | 239 | 18242 | 285500 | 64194751 |
Urine ketone body present | 99.58 | 16.15 | 37 | 18444 | 3270 | 64476981 |
Blood ketone body increased | 98.39 | 16.15 | 25 | 18456 | 607 | 64479644 |
Balanoposthitis | 97.13 | 16.15 | 26 | 18455 | 778 | 64479473 |
Urinary tract infection | 96.54 | 16.15 | 208 | 18273 | 231388 | 64248863 |
Toe amputation | 93.94 | 16.15 | 36 | 18445 | 3464 | 64476787 |
Necrotising fasciitis | 92.21 | 16.15 | 40 | 18441 | 5286 | 64474965 |
Glomerular filtration rate abnormal | 85.60 | 16.15 | 26 | 18455 | 1233 | 64479018 |
Glucose urine present | 78.96 | 16.15 | 26 | 18455 | 1606 | 64478645 |
Pollakiuria | 78.39 | 16.15 | 68 | 18413 | 31462 | 64448789 |
Diabetic metabolic decompensation | 73.00 | 16.15 | 28 | 18453 | 2700 | 64477551 |
Phimosis | 71.81 | 16.15 | 18 | 18463 | 413 | 64479838 |
Type V hyperlipidaemia | 71.16 | 16.15 | 21 | 18460 | 901 | 64479350 |
N-terminal prohormone brain natriuretic peptide increased | 69.13 | 16.15 | 29 | 18452 | 3530 | 64476721 |
Cardiac failure | 65.84 | 16.15 | 128 | 18353 | 132245 | 64348006 |
Hyperglycaemic hyperosmolar nonketotic syndrome | 62.09 | 16.15 | 22 | 18459 | 1697 | 64478554 |
Epididymitis | 61.65 | 16.15 | 22 | 18459 | 1732 | 64478519 |
Urosepsis | 57.65 | 16.15 | 49 | 18432 | 22045 | 64458206 |
Pyelonephritis | 54.97 | 16.15 | 43 | 18438 | 17223 | 64463028 |
Pruritus genital | 52.18 | 16.15 | 17 | 18464 | 1015 | 64479236 |
Toxicity to various agents | 51.35 | 16.15 | 20 | 18461 | 363493 | 64116758 |
Thrombotic cerebral infarction | 50.81 | 16.15 | 14 | 18467 | 468 | 64479783 |
Temperature perception test abnormal | 48.16 | 16.15 | 8 | 18473 | 17 | 64480234 |
Bladder cancer | 47.75 | 16.15 | 33 | 18448 | 10941 | 64469310 |
Drug ineffective | 46.66 | 16.15 | 108 | 18373 | 840139 | 63640112 |
Genital infection female | 45.60 | 16.15 | 9 | 18472 | 64 | 64480187 |
Blood pressure decreased | 44.85 | 16.15 | 85 | 18396 | 86114 | 64394137 |
Thirst | 44.55 | 16.15 | 35 | 18446 | 14102 | 64466149 |
Blood glucose abnormal | 44.03 | 16.15 | 29 | 18452 | 8884 | 64471367 |
Left ventricular dysfunction | 43.01 | 16.15 | 37 | 18444 | 16917 | 64463334 |
Acute myocardial infarction | 42.96 | 16.15 | 74 | 18407 | 69644 | 64410607 |
Acquired phimosis | 42.62 | 16.15 | 8 | 18473 | 42 | 64480209 |
Haematuria | 42.37 | 16.15 | 68 | 18413 | 60403 | 64419848 |
Vulvovaginal pruritus | 42.18 | 16.15 | 17 | 18464 | 1869 | 64478382 |
Genital infection | 41.16 | 16.15 | 8 | 18473 | 52 | 64480199 |
Dysuria | 40.60 | 16.15 | 55 | 18426 | 42002 | 64438249 |
Mitral valve thickening | 39.30 | 16.15 | 11 | 18470 | 390 | 64479861 |
Acetonaemia | 38.59 | 16.15 | 10 | 18471 | 263 | 64479988 |
Pancreatitis acute | 38.30 | 16.15 | 54 | 18427 | 42801 | 64437450 |
Congenital hydrocephalus | 37.92 | 16.15 | 7 | 18474 | 33 | 64480218 |
Suspected COVID-19 | 37.63 | 16.15 | 15 | 18466 | 1602 | 64478649 |
Glycosuria | 37.29 | 16.15 | 16 | 18465 | 2058 | 64478193 |
Hypoglycaemic coma | 37.10 | 16.15 | 20 | 18461 | 4254 | 64475997 |
Body mass index increased | 34.51 | 16.15 | 14 | 18467 | 1565 | 64478686 |
Infusion related reaction | 33.31 | 16.15 | 4 | 18477 | 164463 | 64315788 |
Pancreatitis | 32.52 | 16.15 | 60 | 18421 | 59547 | 64420704 |
Neutropenia | 32.48 | 16.15 | 14 | 18467 | 239610 | 64240641 |
N-terminal prohormone brain natriuretic peptide abnormal | 29.67 | 16.15 | 8 | 18473 | 246 | 64480005 |
Pancreatic carcinoma | 29.11 | 16.15 | 24 | 18457 | 10349 | 64469902 |
Perineal abscess | 28.96 | 16.15 | 9 | 18472 | 461 | 64479790 |
Bladder trabeculation | 28.76 | 16.15 | 6 | 18475 | 58 | 64480193 |
Mitral valve incompetence | 28.70 | 16.15 | 36 | 18445 | 25502 | 64454749 |
Joint swelling | 28.53 | 16.15 | 13 | 18468 | 215369 | 64264882 |
Microalbuminuria | 27.23 | 16.15 | 10 | 18471 | 855 | 64479396 |
Brain stem infarction | 26.14 | 16.15 | 12 | 18469 | 1811 | 64478440 |
Thrombocytopenia | 25.98 | 16.15 | 16 | 18465 | 223785 | 64256466 |
Total cholesterol/HDL ratio increased | 25.88 | 16.15 | 7 | 18474 | 218 | 64480033 |
Mitral valve calcification | 25.86 | 16.15 | 11 | 18470 | 1385 | 64478866 |
Hypersensitivity | 25.80 | 16.15 | 12 | 18469 | 196440 | 64283811 |
Diabetes mellitus | 25.67 | 16.15 | 58 | 18423 | 66416 | 64413835 |
Disease progression | 25.16 | 16.15 | 5 | 18476 | 141675 | 64338576 |
Drug abuse | 24.96 | 16.15 | 4 | 18477 | 132370 | 64347881 |
Acidosis | 24.80 | 16.15 | 28 | 18453 | 17767 | 64462484 |
Obesity | 24.74 | 16.15 | 30 | 18451 | 20532 | 64459719 |
Peripartum cardiomyopathy | 24.48 | 16.15 | 6 | 18475 | 125 | 64480126 |
Vomiting | 24.41 | 16.15 | 253 | 18228 | 550864 | 63929387 |
Arthropathy | 24.35 | 16.15 | 3 | 18478 | 120964 | 64359287 |
Shock | 24.09 | 16.15 | 41 | 18440 | 38199 | 64442052 |
White blood cell count decreased | 23.41 | 16.15 | 8 | 18473 | 157829 | 64322422 |
Hyperuricaemia | 23.36 | 16.15 | 21 | 18460 | 10170 | 64470081 |
Pain | 23.34 | 16.15 | 81 | 18400 | 553430 | 63926821 |
Treatment failure | 23.26 | 16.15 | 3 | 18478 | 116813 | 64363438 |
Decreased vibratory sense | 22.97 | 16.15 | 8 | 18473 | 586 | 64479665 |
Genital infection fungal | 22.83 | 16.15 | 6 | 18475 | 167 | 64480084 |
Gangrene | 22.76 | 16.15 | 18 | 18463 | 7320 | 64472931 |
Musculoskeletal stiffness | 22.62 | 16.15 | 4 | 18477 | 123202 | 64357049 |
Immune-mediated hepatitis | 22.59 | 16.15 | 12 | 18469 | 2477 | 64477774 |
Hyperkalaemia | 22.56 | 16.15 | 72 | 18409 | 101057 | 64379194 |
Perineal pain | 22.29 | 16.15 | 9 | 18472 | 994 | 64479257 |
Low density lipoprotein increased | 21.91 | 16.15 | 18 | 18463 | 7722 | 64472529 |
Foot amputation | 21.68 | 16.15 | 8 | 18473 | 693 | 64479558 |
Cardiac failure chronic | 21.46 | 16.15 | 19 | 18462 | 9022 | 64471229 |
Urinary retention | 21.35 | 16.15 | 45 | 18436 | 49156 | 64431095 |
Condition aggravated | 21.27 | 16.15 | 47 | 18434 | 372379 | 64107872 |
Ejection fraction decreased | 21.09 | 16.15 | 33 | 18448 | 28674 | 64451577 |
Hypertrophy | 21.05 | 16.15 | 8 | 18473 | 752 | 64479499 |
Renal atrophy | 20.91 | 16.15 | 10 | 18471 | 1654 | 64478597 |
Pyrexia | 20.79 | 16.15 | 86 | 18395 | 558558 | 63921693 |
Hypernatraemia | 20.17 | 16.15 | 21 | 18460 | 12168 | 64468083 |
High density lipoprotein decreased | 19.88 | 16.15 | 13 | 18468 | 3933 | 64476318 |
Vaccination failure | 19.82 | 16.15 | 8 | 18473 | 883 | 64479368 |
Urinary tract infection fungal | 19.78 | 16.15 | 8 | 18473 | 887 | 64479364 |
COVID-19 pneumonia | 19.72 | 16.15 | 24 | 18457 | 16480 | 64463771 |
Polydipsia | 19.62 | 16.15 | 15 | 18466 | 5806 | 64474445 |
Polycythaemia | 19.23 | 16.15 | 10 | 18471 | 1977 | 64478274 |
Renal impairment | 19.10 | 16.15 | 83 | 18398 | 134934 | 64345317 |
Vulvovaginal candidiasis | 18.58 | 16.15 | 10 | 18471 | 2120 | 64478131 |
Diabetic retinopathy | 18.46 | 16.15 | 11 | 18470 | 2828 | 64477423 |
Pancytopenia | 18.43 | 16.15 | 9 | 18472 | 143300 | 64336951 |
Febrile neutropenia | 18.42 | 16.15 | 16 | 18465 | 187641 | 64292610 |
Heat illness | 18.12 | 16.15 | 6 | 18475 | 377 | 64479874 |
Malignant neoplasm progression | 18.03 | 16.15 | 5 | 18476 | 112866 | 64367385 |
Coronary artery stenosis | 17.94 | 16.15 | 19 | 18462 | 11229 | 64469022 |
Bladder transitional cell carcinoma | 17.74 | 16.15 | 10 | 18471 | 2320 | 64477931 |
Urine ketone body | 17.60 | 16.15 | 5 | 18476 | 187 | 64480064 |
Depression | 17.54 | 16.15 | 16 | 18465 | 183275 | 64296976 |
Food refusal | 17.11 | 16.15 | 6 | 18475 | 449 | 64479802 |
Urine output increased | 16.97 | 16.15 | 9 | 18472 | 1852 | 64478399 |
Aortic valve incompetence | 16.88 | 16.15 | 16 | 18465 | 8285 | 64471966 |
Insulin C-peptide decreased | 16.88 | 16.15 | 4 | 18477 | 72 | 64480179 |
Diabetic ketoacidotic hyperglycaemic coma | 16.82 | 16.15 | 5 | 18476 | 220 | 64480031 |
Contraindicated product administered | 16.81 | 16.15 | 5 | 18476 | 107824 | 64372427 |
Pneumonia | 16.81 | 16.15 | 93 | 18388 | 559483 | 63920768 |
Pyelonephritis acute | 16.80 | 16.15 | 13 | 18468 | 5121 | 64475130 |
Abnormal loss of weight | 16.47 | 16.15 | 15 | 18466 | 7385 | 64472866 |
Candida infection | 16.35 | 16.15 | 31 | 18450 | 31388 | 64448863 |
None
Source | Code | Description |
---|---|---|
ATC | A10BD15 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD21 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD25 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BK01 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Sodium-glucose co-transporter 2 (SGLT2) inhibitors |
MeSH PA | D007004 | Hypoglycemic Agents |
MeSH PA | D000077203 | Sodium-Glucose Transporter 2 Inhibitors |
FDA MoA | N0000187058 | Sodium-Glucose Transporter 2 Inhibitors |
FDA EPC | N0000187059 | Sodium-Glucose Cotransporter 2 Inhibitor |
CHEBI has role | CHEBI:35526 | antidiabetic |
CHEBI has role | CHEBI:73273 | sodium-glucose transport protein subtype 2 inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
Diabetes mellitus type 1 | indication | 46635009 | DOID:9744 |
Chronic heart failure | indication | 48447003 | |
Chronic kidney disease | indication | 709044004 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 11.62 | acidic |
pKa2 | 13.26 | acidic |
pKa3 | 13.7 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
10MG;EQ 5MG BASE | QTERN | ASTRAZENECA AB | N209091 | Feb. 27, 2017 | RX | TABLET | ORAL | RE44186 | July 31, 2023 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;EQ 5MG BASE | QTERN | ASTRAZENECA AB | N209091 | May 2, 2019 | RX | TABLET | ORAL | RE44186 | July 31, 2023 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | RE44186 | July 31, 2023 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
2.5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | RE44186 | July 31, 2023 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | RE44186 | July 31, 2023 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | RE44186 | July 31, 2023 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 9238076 | April 15, 2024 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 9238076 | April 15, 2024 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8431685 | April 13, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8461105 | April 13, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8431685 | April 13, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8461105 | April 13, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 7456254 | June 30, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 7456254 | June 30, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
10MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
2.5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | July 28, 2017 | RX | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG;EQ 5MG BASE | QTERN | ASTRAZENECA AB | N209091 | Feb. 27, 2017 | RX | TABLET | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;EQ 5MG BASE | QTERN | ASTRAZENECA AB | N209091 | May 2, 2019 | RX | TABLET | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
2.5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8329648 | Aug. 18, 2026 | REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8329648 | Aug. 18, 2026 | REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8329648 | Aug. 18, 2026 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8906851 | Aug. 18, 2026 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8329648 | Aug. 18, 2026 | REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8329648 | Aug. 18, 2026 | REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8329648 | Aug. 18, 2026 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8906851 | Aug. 18, 2026 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
2.5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | July 28, 2017 | RX | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG;EQ 5MG BASE | QTERN | ASTRAZENECA AB | N209091 | Feb. 27, 2017 | RX | TABLET | ORAL | 8501698 | June 20, 2027 | METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN |
10MG;EQ 5MG BASE | QTERN | ASTRAZENECA AB | N209091 | Feb. 27, 2017 | RX | TABLET | ORAL | 8501698 | June 20, 2027 | METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN |
10MG;EQ 5MG BASE | QTERN | ASTRAZENECA AB | N209091 | Feb. 27, 2017 | RX | TABLET | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;EQ 5MG BASE | QTERN | ASTRAZENECA AB | N209091 | May 2, 2019 | RX | TABLET | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
2.5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8361972 | March 21, 2028 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8361972 | March 21, 2028 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8361972 | March 21, 2028 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8361972 | March 21, 2028 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
10MG;EQ 5MG BASE | QTERN | ASTRAZENECA AB | N209091 | Feb. 27, 2017 | RX | TABLET | ORAL | 8361972 | March 21, 2028 | METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN |
10MG;EQ 5MG BASE | QTERN | ASTRAZENECA AB | N209091 | Feb. 27, 2017 | RX | TABLET | ORAL | 8361972 | March 21, 2028 | METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN |
10MG;EQ 5MG BASE | QTERN | ASTRAZENECA AB | N209091 | Feb. 27, 2017 | RX | TABLET | ORAL | 8361972 | March 21, 2028 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;EQ 5MG BASE | QTERN | ASTRAZENECA AB | N209091 | May 2, 2019 | RX | TABLET | ORAL | 8361972 | March 21, 2028 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8685934 | May 26, 2030 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 8685934 | May 26, 2030 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE |
10MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8685934 | May 26, 2030 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE |
10MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8685934 | May 26, 2030 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE |
2.5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | July 28, 2017 | RX | TABLET, EXTENDED RELEASE | ORAL | 8685934 | May 26, 2030 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE |
5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8685934 | May 26, 2030 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE |
5MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8685934 | May 26, 2030 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | 10973836 | March 9, 2040 | REDUCTION OF THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND WITHOUT TYPE II DIABETES |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | Feb. 22, 2022 | INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO REFLECT THAT NO DOSE ADJUSTMENT IS NEEDED FOR PATIENTS WITH AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OF 45 ML/MIN/1.73 M2 OR GREATER AS SUPPORTED BY CLINICAL STUDY REPORT |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | Feb. 22, 2022 | INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO REFLECT THAT NO DOSE ADJUSTMENT IS NEEDED FOR PATIENTS WITH AN ESTIMATED GLOMERULAR FILTRATION RATE (EGFR) OF 45 ML/MIN/1.73 M2 OR GREATER AS SUPPORTED BY CLINICAL STUDY REPORT |
10MG;EQ 5MG BASE | QTERN | ASTRAZENECA AB | N209091 | Feb. 27, 2017 | RX | TABLET | ORAL | May 2, 2022 | EXPANDED INDICATION FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS |
5MG;EQ 5MG BASE | QTERN | ASTRAZENECA AB | N209091 | May 2, 2019 | RX | TABLET | ORAL | May 2, 2022 | NEW STRENGTH |
10MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | May 2, 2022 | NEW PRODUCT |
2.5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | May 2, 2022 | NEW PRODUCT |
5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | May 2, 2022 | NEW PRODUCT |
5MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | May 2, 2022 | NEW PRODUCT |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
10MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
10MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
2.5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | July 28, 2017 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
5MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | May 5, 2023 | TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE (NYHA CLASS II-IV) WITH REDUCED EJECTION FRACTION |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | May 5, 2023 | TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE (NYHA CLASS II-IV) WITH REDUCED EJECTION FRACTION |
10MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | April 30, 2024 | TO REDUCE THE RISK OF SUSTAINED EGFR DECLINE, END-STAGE KIDNEY DISEASE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION |
5MG | FARXIGA | ASTRAZENECA AB | N202293 | Jan. 8, 2014 | RX | TABLET | ORAL | April 30, 2024 | TO REDUCE THE RISK OF SUSTAINED EGFR DECLINE, END-STAGE KIDNEY DISEASE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sodium/glucose cotransporter 2 | Transporter | INHIBITOR | IC50 | 9.30 | IUPHAR | IUPHAR | |||
Sodium/glucose cotransporter 1 | Transporter | IC50 | 8.49 | CHEMBL | |||||
Sodium/myo-inositol cotransporter 2 | Transporter | IC50 | 6.42 | CHEMBL | |||||
Low affinity sodium-glucose cotransporter | Transporter | IC50 | 8.87 | CHEMBL | |||||
Sodium/glucose cotransporter 2 | Transporter | EC50 | 8.52 | CHEMBL |
ID | Source |
---|---|
D08897 | KEGG_DRUG |
960404-48-2 | SECONDARY_CAS_RN |
4033035 | VANDF |
CHEBI:85078 | CHEBI |
CHEMBL429910 | ChEMBL_ID |
CHEMBL2103802 | ChEMBL_ID |
C529054 | MESH_SUPPLEMENTAL_RECORD_UI |
4594 | IUPHAR_LIGAND_ID |
8886 | INN_ID |
DB06292 | DRUGBANK_ID |
1ULL0QJ8UC | UNII |
9887712 | PUBCHEM_CID |
1486966 | RXNORM |
210769 | MMSL |
28989 | MMSL |
29986 | MMSL |
d07928 | MMSL |
014949 | NDDF |
014950 | NDDF |
703674001 | SNOMEDCT_US |
703675000 | SNOMEDCT_US |
703678003 | SNOMEDCT_US |
783086004 | SNOMEDCT_US |
C2353951 | UMLSCUI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
FARXIGA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0310-6205 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 27 sections |
FARXIGA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0310-6210 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 27 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6225 | TABLET, FILM COATED, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6225 | TABLET, FILM COATED, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6250 | TABLET, FILM COATED, EXTENDED RELEASE | 5 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6250 | TABLET, FILM COATED, EXTENDED RELEASE | 5 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6260 | TABLET, FILM COATED, EXTENDED RELEASE | 5 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6260 | TABLET, FILM COATED, EXTENDED RELEASE | 5 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6270 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6270 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6280 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6280 | TABLET, FILM COATED, EXTENDED RELEASE | 10 mg | ORAL | NDA | 30 sections |
QTERN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6770 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 28 sections |
QTERN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6770 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 28 sections |
QTERN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6780 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 28 sections |
QTERN | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6780 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 28 sections |
FARXIGA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3481 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 27 sections |
FARXIGA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3482 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 27 sections |
FARXIGA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-6932 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 27 sections |
FARXIGA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-6932 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 27 sections |
FARXIGA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-6933 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 27 sections |
FARXIGA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-6933 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 27 sections |